Drugmaker Merck announced on Thursday that the U.S. Food and Drug Administration (FDA) has approved Lipfendra, a daily pill designed to lower high levels of LDL cholesterol, commonly known as 'bad cholesterol.' The medication is a PCSK9 inhibitor and can be used either in conjunction with statins or as an alternative for patients who cannot tolerate statins or need additional LDL reduction.
Clinical Trial Results Show Significant LDL Reduction
Clinical trials demonstrated that Lipfendra can dramatically reduce LDL cholesterol levels. According to The New York Times, the drug brought LDL levels down to 50 or 60 mg/dL, and in some cases even lower. This is well below the recommended targets set by the American College of Cardiology and the American Heart Association, which advise LDL levels under 100 mg/dL for most patients and under 55 mg/dL for those at very high risk of atherosclerotic cardiovascular disease (ASCVD).
Addressing Statin Limitations
Statins have been the cornerstone of cholesterol treatment for decades and are the most prescribed medication in the United States. However, they are not always effective for all patients. Dr. Paja Banka, associate vice-president for global clinical development at Merck and a pediatric cardiologist, noted that '70% of patients are not getting to their LDL goal.' Statins can also cause side effects such as muscle aches, which Lipfendra appears to avoid. Dr. Banka stated that the side effects observed in trials were minimal and 'like the placebo,' with no muscle aches reported.
Pill Formulation Expected to Increase Accessibility
Previously, PCSK9 inhibitors were only available as injections, which limited their use. The new pill formulation is expected to make the therapy more widely accessible. Merck indicated that Lipfendra should be available in pharmacies within weeks. The company set the list price at $10.50 per day, or over $300 per month, but anticipates that out-of-pocket costs for many patients will be lower due to insurance coverage and other factors.
Impact on Heart Disease Prevention
Heart disease remains the leading cause of death in the United States, and elevated LDL cholesterol is a key contributor to ASCVD, which involves plaque buildup in arteries. Lowering LDL levels is critical for preventing heart attacks and strokes. The new guidelines from the American College of Cardiology and the American Heart Association, issued in March, emphasize aggressive LDL targets: below 100 mg/dL for borderline or intermediate risk, below 70 mg/dL for high risk, and below 55 mg/dL for those with ASCVD at very high risk. Lipfendra's ability to achieve these targets could have a significant public health impact.
